The analysis, published by the Association of the British Pharmaceutical Industry (ABPI), is an encouraging sign but “is not yet enough to restore the UK’s global ranking on trials ...

The ABPI’s chief executive Dr Richard Torbett shares his views on how the industry has adapted to COVID-19 and explains why the post-pandemic future is looking bright for the UK industry.

The five-year voluntary pricing deal between pharma companies and the U.K. Department of Health is under severe pressure after the rebate the industry is due to pay leapt from 15.3% in 2024 to 22.9% ...